Node-RADS surpasses ESGAR criteria for MRI rectal cancer nodal staging

In a 780-patient study with external validation, Node-RADS and its simplified version (recSNAP) beat ESGAR criteria for MRI-based rectal cancer nodal staging (AUC 0.83 vs 0.71, P<.001). Interobserver agreement was substantial (κ=0.76).

• At the optimal threshold (score ≥3), Node-RADS was simplified to recSNAP, achieving node-level AUC 0.83 vs ESGAR 0.71 (P<.001).
• For post-neoadjuvant patients, Node-RADS with threshold ≥4 also outperformed ESGAR (AUC 0.72 vs 0.66, P<.001).
• Two-reader interobserver agreement for Node-RADS was substantial (κ=0.76 pre-treatment, 0.64 post-treatment).

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.